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, 2008 saw the 25 th anniversary of the US Orphan Drug Act (ODA), which was promulgated in recognition of the economic barriers to developing drugs for rare diseases (defined as those that affect fewer than 200,000 persons in the United States) 2 . The ODA encourages the development of promising new compounds by providing significant fiscal benefits: FDA-enforced marketing exclusivity, tax credits and fee exemptions. These products are designated 'orphan products' by the FDA's Office of Orphan Products Development, and if shown to be safe and effective can be approved for marketing. As of 20 July 2009, 343 orphan products have been marketed to treat rare diseases 3 . By contrast, only 10 such products were approved in the 10 years preceding the ODA 4 . The ODA has been credited not only with offering new hope for those who suffer from rare diseases, but also with nurturing an expanding biotechnology sector and personalizing drug development 5, 6 . In a time of relative contraction in the development of new small-molecule therapeutics, orphan drug development has emerged as a burgeoning sector of the pharmaceutical industry. This correspondence documents its growth.
We used internal and publicly available data on first-time FDA approvals 3,7 from January 1983 through to December 2008. We categorized approvals as 'drugs' if marketing authorization was gained under a New Drug Application (NDA) or as 'biologics' if under a Biologics License Application (BLA). We further classified these approvals as 'orphan' or 'non-orphan' , depending on whether the product held an antecedent orphan designation. Only new drugs and biologics were considered; we did not include efficacy supplements (applications for new indications of already approved drugs) or formulation changes.
In 1983, the year when the ODA was signed, there was 1 new orphan drug approval and no new orphan biologic approvals. In summary, orphan products now represent roughly one-third of all FDA newly approved drugs and biologics. As pharmacogenomics increasingly resolves specific therapeutic targets, we expect more orphan treatments for people with rare diseases. There are at least 6,000 rare diseases that collectively affect 25 million Americans 8 , and these trends hold promise for future therapies for such diseases. 
